Furthermore, a recent phase 1/2 trial (PIVOT-02) reported an extended PFS and an acceptable rate of grade 3/4 adverse effects in response to the administration of bempegaldesleukin (a CD122-preferential interleukin 2 pathway agonist) plus nivolumab as first-line treatment for metastatic melanoma (70). This evidence concerns the gene IL2RB and metastatic melanoma.